9th Antifibrotic Drug Development Summit

The antifibrotic field is at an inflection point: Madrigal’s Resmetirom secured the first-ever MASH approval in 2024, Boehringer’s nerandomilast hit its Phase 3 endpoint in IPF, and pharma giants like Lilly and GSK are investing billions in fibrosis pipelines. Yet, with GLP-1s reshaping metabolic disease treatment and organ-specific challenges persisting, developers must now prove differentiation, whether through novel targets, biomarker strategies, or pan-fibrotic mechanisms.
Tackle these shared challenges alongside 80+ leaders from Pfizer, Novartis, Gilead Sciences, and pioneering biotechs at the 9th Antifibrotic Drug Development Summit - the only cross-fibrosis industry summit bridging discovery to Phase 2, across IPF, MASH, kidney, cardiac, and systemic sclerosis fibrosis.